In: Annals of Oncology, 2002, vol. 13, no. 4, p. 566-575
|
In: Annals of Oncology, 2006, vol. 18, no. 1, p. 36-39
|
In: Annals of Oncology, 2005, vol. 16, no. 5, p. 762-766
|
In: Annals of Oncology, 2006, vol. 18, no. 2, p. 299-304
|
In: Annals of Oncology, 2015, vol. 26, no. 4, p. 702-708
|
In: International Journal for Quality in Health Care, 2006, vol. 18, no. 3, p. 177-182
|
In: Annals of Oncology, 1998, vol. 9, no. 5, p. 535-541
|
In: Oncotarget, 2015, vol. 6, no. 16, p. 14300–14317
Carcinoma-associated fibroblasts were reported to promote colorectal cancer (CRC) invasion by secreting motility factors and extracellular matrix processing enzymes. Less is known whether fibroblasts may induce CRC cancer cell motility by contact- dependent mechanisms. To address this question we characterized the interaction between fibroblasts and SW620 and HT29 colorectal cancer cells in 2D...
|
In: Oncogene, 2012, vol. 31, p. 48-59
Cyclooxyganase-2 (COX-2), a rate-limiting enzyme in the prostaglandin synthesis pathway, is overexpressed in many cancers and contributes to cancer progression through tumor cell-autonomous and paracrine effects. Regular use of non-steroidal anti-inflammatory drugs or selective COX-2 inhibitors (COXIBs) reduces the risk of cancer development and progression, in particular of the colon. The COXIB...
|